ValuEngine upgraded shares of Momenta Pharmaceuticals (NASDAQ:MNTA) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning.
A number of other equities research analysts have also issued reports on the company. BidaskClub lowered Momenta Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, March 27th. Stifel Nicolaus raised Momenta Pharmaceuticals from a hold rating to a buy rating and raised their price target for the stock from $18.00 to $21.00 in a research note on Thursday, February 22nd. Finally, Zacks Investment Research raised Momenta Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $15.33.
Shares of Momenta Pharmaceuticals stock opened at $17.50 on Tuesday. The company has a market capitalization of $1,379.61, a PE ratio of -14.58 and a beta of 1.64. Momenta Pharmaceuticals has a one year low of $11.85 and a one year high of $19.25.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.12. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. The firm had revenue of $64.60 million during the quarter, compared to analyst estimates of $66.59 million. During the same period last year, the company earned $0.60 EPS. Momenta Pharmaceuticals’s quarterly revenue was up 88.9% compared to the same quarter last year. research analysts forecast that Momenta Pharmaceuticals will post -1.27 earnings per share for the current year.
In other Momenta Pharmaceuticals news, Director Elizabeth Stoner sold 16,264 shares of Momenta Pharmaceuticals stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $18.00, for a total transaction of $292,752.00. Following the completion of the sale, the director now directly owns 32,440 shares of the company’s stock, valued at approximately $583,920. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Bruce Leicher sold 1,861 shares of Momenta Pharmaceuticals stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $16.00, for a total value of $29,776.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 70,836 shares of company stock valued at $1,158,448. 4.40% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of MNTA. LS Investment Advisors LLC raised its position in Momenta Pharmaceuticals by 59.8% during the 4th quarter. LS Investment Advisors LLC now owns 9,300 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 3,479 shares in the last quarter. Amalgamated Bank bought a new stake in Momenta Pharmaceuticals during the 4th quarter valued at $152,000. Landscape Capital Management L.L.C. bought a new stake in Momenta Pharmaceuticals during the 4th quarter valued at $159,000. Xact Kapitalforvaltning AB bought a new stake in Momenta Pharmaceuticals during the 4th quarter valued at $163,000. Finally, Sicart Associates LLC bought a new stake in Momenta Pharmaceuticals during the 4th quarter valued at $279,000. 97.64% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/momenta-pharmaceuticals-mnta-upgraded-to-buy-by-valuengine.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.